Impact of chemotherapy-induced neutropenia on quality of life: A prospective pilot investigation

Barry V. Fortner, Lee Schwartzberg, Kurt Tauer, Arthur C. Houts, James Hackett, Brad S. Stolshek

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: In this exploratory, prospective study evaluated quality of life (QoL) changes in patients with diverse cancers during the first cycle of myelosuppressive chemotherapy. Patients and methods: Of 80 patients enrolled, 71 were observed during one of five chemotherapy regimens: docetaxel; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); carboplatin-paclitaxel; carboplatin-docetaxel; and carboplatin-gemcitabine. Complete blood counts were taken weekly. QoL and symptom burden measures were administered at baseline and throughout the cycle, and included SF-36, Cancer Care Monitor (CCM), Hospital Anxiety and Depression Scale (HADS), and Psychosocial Adjustment to Illness Scale (PAIS). Using generalized estimating equations, we modeled the change in each measure from baseline to the end of each week using the following covariates: baseline QoL measure, baseline SF-36 Physical and Mental Health Summary scores, sex, age, cycle week, grade 4 neutropenia any time in the past 7 days (yes/no), and the interaction of the latter two covariates. Results: Of the 71 patients observed, 33 developed grade 4 neutropenia during the first 2 weeks. Changes from baseline in SF-36 Bodily Pain, HADS Anxiety, and PAIS Social Environment scores were significantly less favorable (P<0.05) when patients experienced grade 4 neutropenia any time in the past 7 days compared to when they did not (grade 0-3). A similar, but non-significant, trend was also observed for 12 other QoL measures. Conclusion: QoL may be adversely affected up to 7 days after patients experience grade 4 (versus grade 0-3) neutropenia. Such findings need to be examined further in studies with adequate statistical power to test a priori hypotheses regarding specific QoL measures.

Original languageEnglish (US)
Pages (from-to)522-528
Number of pages7
JournalSupportive Care in Cancer
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2005

Fingerprint

Neutropenia
Quality of Life
docetaxel
Drug Therapy
Carboplatin
Social Adjustment
Anxiety
gemcitabine
Depression
Blood Cell Count
Social Environment
Vincristine
Prednisone
Paclitaxel
Doxorubicin
Cyclophosphamide
Neoplasms
Mental Health
Prospective Studies
Pain

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Impact of chemotherapy-induced neutropenia on quality of life : A prospective pilot investigation. / Fortner, Barry V.; Schwartzberg, Lee; Tauer, Kurt; Houts, Arthur C.; Hackett, James; Stolshek, Brad S.

In: Supportive Care in Cancer, Vol. 13, No. 7, 01.07.2005, p. 522-528.

Research output: Contribution to journalArticle

Fortner, Barry V. ; Schwartzberg, Lee ; Tauer, Kurt ; Houts, Arthur C. ; Hackett, James ; Stolshek, Brad S. / Impact of chemotherapy-induced neutropenia on quality of life : A prospective pilot investigation. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 7. pp. 522-528.
@article{07f1227b10de487891399ac671d0210a,
title = "Impact of chemotherapy-induced neutropenia on quality of life: A prospective pilot investigation",
abstract = "Purpose: In this exploratory, prospective study evaluated quality of life (QoL) changes in patients with diverse cancers during the first cycle of myelosuppressive chemotherapy. Patients and methods: Of 80 patients enrolled, 71 were observed during one of five chemotherapy regimens: docetaxel; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); carboplatin-paclitaxel; carboplatin-docetaxel; and carboplatin-gemcitabine. Complete blood counts were taken weekly. QoL and symptom burden measures were administered at baseline and throughout the cycle, and included SF-36, Cancer Care Monitor (CCM), Hospital Anxiety and Depression Scale (HADS), and Psychosocial Adjustment to Illness Scale (PAIS). Using generalized estimating equations, we modeled the change in each measure from baseline to the end of each week using the following covariates: baseline QoL measure, baseline SF-36 Physical and Mental Health Summary scores, sex, age, cycle week, grade 4 neutropenia any time in the past 7 days (yes/no), and the interaction of the latter two covariates. Results: Of the 71 patients observed, 33 developed grade 4 neutropenia during the first 2 weeks. Changes from baseline in SF-36 Bodily Pain, HADS Anxiety, and PAIS Social Environment scores were significantly less favorable (P<0.05) when patients experienced grade 4 neutropenia any time in the past 7 days compared to when they did not (grade 0-3). A similar, but non-significant, trend was also observed for 12 other QoL measures. Conclusion: QoL may be adversely affected up to 7 days after patients experience grade 4 (versus grade 0-3) neutropenia. Such findings need to be examined further in studies with adequate statistical power to test a priori hypotheses regarding specific QoL measures.",
author = "Fortner, {Barry V.} and Lee Schwartzberg and Kurt Tauer and Houts, {Arthur C.} and James Hackett and Stolshek, {Brad S.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1007/s00520-004-0757-4",
language = "English (US)",
volume = "13",
pages = "522--528",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Impact of chemotherapy-induced neutropenia on quality of life

T2 - A prospective pilot investigation

AU - Fortner, Barry V.

AU - Schwartzberg, Lee

AU - Tauer, Kurt

AU - Houts, Arthur C.

AU - Hackett, James

AU - Stolshek, Brad S.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Purpose: In this exploratory, prospective study evaluated quality of life (QoL) changes in patients with diverse cancers during the first cycle of myelosuppressive chemotherapy. Patients and methods: Of 80 patients enrolled, 71 were observed during one of five chemotherapy regimens: docetaxel; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); carboplatin-paclitaxel; carboplatin-docetaxel; and carboplatin-gemcitabine. Complete blood counts were taken weekly. QoL and symptom burden measures were administered at baseline and throughout the cycle, and included SF-36, Cancer Care Monitor (CCM), Hospital Anxiety and Depression Scale (HADS), and Psychosocial Adjustment to Illness Scale (PAIS). Using generalized estimating equations, we modeled the change in each measure from baseline to the end of each week using the following covariates: baseline QoL measure, baseline SF-36 Physical and Mental Health Summary scores, sex, age, cycle week, grade 4 neutropenia any time in the past 7 days (yes/no), and the interaction of the latter two covariates. Results: Of the 71 patients observed, 33 developed grade 4 neutropenia during the first 2 weeks. Changes from baseline in SF-36 Bodily Pain, HADS Anxiety, and PAIS Social Environment scores were significantly less favorable (P<0.05) when patients experienced grade 4 neutropenia any time in the past 7 days compared to when they did not (grade 0-3). A similar, but non-significant, trend was also observed for 12 other QoL measures. Conclusion: QoL may be adversely affected up to 7 days after patients experience grade 4 (versus grade 0-3) neutropenia. Such findings need to be examined further in studies with adequate statistical power to test a priori hypotheses regarding specific QoL measures.

AB - Purpose: In this exploratory, prospective study evaluated quality of life (QoL) changes in patients with diverse cancers during the first cycle of myelosuppressive chemotherapy. Patients and methods: Of 80 patients enrolled, 71 were observed during one of five chemotherapy regimens: docetaxel; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); carboplatin-paclitaxel; carboplatin-docetaxel; and carboplatin-gemcitabine. Complete blood counts were taken weekly. QoL and symptom burden measures were administered at baseline and throughout the cycle, and included SF-36, Cancer Care Monitor (CCM), Hospital Anxiety and Depression Scale (HADS), and Psychosocial Adjustment to Illness Scale (PAIS). Using generalized estimating equations, we modeled the change in each measure from baseline to the end of each week using the following covariates: baseline QoL measure, baseline SF-36 Physical and Mental Health Summary scores, sex, age, cycle week, grade 4 neutropenia any time in the past 7 days (yes/no), and the interaction of the latter two covariates. Results: Of the 71 patients observed, 33 developed grade 4 neutropenia during the first 2 weeks. Changes from baseline in SF-36 Bodily Pain, HADS Anxiety, and PAIS Social Environment scores were significantly less favorable (P<0.05) when patients experienced grade 4 neutropenia any time in the past 7 days compared to when they did not (grade 0-3). A similar, but non-significant, trend was also observed for 12 other QoL measures. Conclusion: QoL may be adversely affected up to 7 days after patients experience grade 4 (versus grade 0-3) neutropenia. Such findings need to be examined further in studies with adequate statistical power to test a priori hypotheses regarding specific QoL measures.

UR - http://www.scopus.com/inward/record.url?scp=21644479915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644479915&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0757-4

DO - 10.1007/s00520-004-0757-4

M3 - Article

C2 - 15678345

AN - SCOPUS:21644479915

VL - 13

SP - 522

EP - 528

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 7

ER -